The Association between the Vascular Endothelial Growth Factor–to–Cancer Antigen 125 Ratio in Peritoneal Dialysis Effluent and the Epithelial-to-Mesenchymal Transition in Continuous Ambulatory Peritoneal Dialysis
Restricted accessResearch articleFirst published online June, 2008
The Association between the Vascular Endothelial Growth Factor–to–Cancer Antigen 125 Ratio in Peritoneal Dialysis Effluent and the Epithelial-to-Mesenchymal Transition in Continuous Ambulatory Peritoneal Dialysis
We examined peritoneal growth factors, mesothelial mass, and epithelial-to-mesenchymal transition (EMT) in response to peritoneal exposure to peritoneal dialysate with standard and low concentrations of glucose degradation products (GDPs). We randomized 56 incident continuous ambulatory peritoneal dialysis (CAPD) patients to receive either low-GDP (30 patients) or high-GDP (standard) peritoneal dialysis (PD) solution (26 patients). The effects of the PD solutions on EMT and peritoneal growth factors in overnight dialysate effluent were compared at 1, 6, and 12 months. Assessment of EMT was performed after human peritoneal mesothelial cells (HPMCs) were cultured from overnight effluent. The low-GDP solution group showed significantly higher dialysate levels of cancer antigen 125 (CA125), fibronectin, transforming growth factor β(TGFβ)–induced gene product (βig-h3), and interleukin-6 (IL-6), but the rate of EMT was significantly lower in the low-GDP solution group during the initial 12 months of CAPD treatment. After adjusting peritoneal growth factors for dialysate CA125 concentration, the low-GDP solution group showed significantly lower ratios of fibronectin/CA125, βig-h3/CA125, IL-6/CA125, TGFβ/CA125, and vascular endothelial growth factor (VEGF)/CA125 than did patients in the high-GDP (standard) solution group. Factors associated with higher EMT were the type of solution (high in GDPs), the mass of HPMCs (low CA125), and higher VEGF/CA125. Adjustment of dialysate VEGF for effluent CA125 revealed a significant association with EMT. It suggests that fibroblastoid transition from HPMCs could be affected by the intraperitoneal VEGF per unit mass of HPMCs.
WitowskiJWisniewskaJKorybalskaKBenderTOBreborowiczAGahlGM. Prolonged exposure to glucose degradation products impairs viability and function of human peritoneal mesothelial cells. J Am Soc Nephrol2001; 12:2434–41.
2.
DoJYKimYLParkJWChoKHKimTWYoonKW. The effect of low glucose degradation product dialysis solution on epithelial-to-mesenchymal transition in continuous ambulatory peritoneal dialysis patients. Perit Dial Int2005; 25(Suppl 3):S14–17.
3.
StylianouEJennerLADaviesMColesGAWilliamsJD. Isolation, culture and characterization of human peritoneal mesothelial cells. Kidney Int1990; 37:1563–70.
4.
WilliamsJDTopleyNCraigKJMackenzieRKPischetsriederMLageC. The Euro-Balance Trial: the effect of a new biocompatible peritoneal dialysis fluid (Balance) on the peritoneal membrane. Kidney Int2004; 66:408–18.
5.
KimYLDoJYParkSHChoKParkJYoonK. Low glucose degradation products dialysis solution modulates the levels of surrogate markers of peritoneal inflammation, integrity, and angiogenesis: preliminary report. Nephrology (Carlton)2003; 8(Suppl):S28–32.
6.
MargettsPJBonniaudP.Basic mechanisms and clinical implications of peritoneal fibrosis. Perit Dial Int2003; 23:530–41.
7.
AroeiraLSAguileraASelgasRRamírez–HuescaMPérez–LozanoMLCirugedaA. Mesenchymal conversion of mesothelial cells as a mechanism responsible for high solute transport rate in peritoneal dialysis: role of vascular endothelial growth factor. Am J Kidney Dis2005; 46:938–48.
8.
Yáñez–MóMLara–PezziESelgasRRamírez–HuescaMDomínguez–JiménezCJiménez–HeffernanJA. Peritoneal dialysis and epithelial-to-mesenchymal transition of mesothelial cells. N Engl J Med2003; 348:403–13.
9.
SelgasRBajoAJiménez–HeffernanJASánchez–TomeroJADel PesoGAguileraA. Epithelial-to-mesenchymal transition of the mesothelial cell—its role in the response of the peritoneum to dialysis. Nephrol Dial Transplant2006; 21(Suppl 2):ii2–7.
10.
López–CabreraMAguileraAAroeiraLSRamírez–HuescaMPérez–LozanoMLJiménez–HeffernanJA. Ex vivo analysis of dialysis effluent-derived mesothelial cells as an approach to unveiling the mechanism of peritoneal membrane failure. Perit Dial Int2006; 26:26–34.
11.
TopleyNMichaelDBowenT.CA125: holy grail or a poisoned chalice. Nephron Clin Pract2005; 100:c52–4.
12.
BreborowiczABreborowiczMPydaMPolubinskaAOreopoulosD.Limitations of CA125 as an index of peritoneal mesothelial cell mass. Nephrol Clin Pract2005; 100:c46–51
13.
LiuY.Epithelial to mesenchymal transition in renal fibrogenesis: pathologic significance, molecular mechanism, and therapeutic intervention. J Am Soc Nephrol2004; 15:1–12.
